Merck kgaa, darmstadt, germany and burning rock collaborate on liquid-biopsy based cdx development using burning rock's oncocompass target™

Guangzhou, china, nov. 17, 2021 (globe newswire) -- burning rock biotech limited (nasdaq: bnr, the “company” or “burning rock”) today announced a strategic partnership with merck kgaa, darmstadt, germany, in companion diagnostics (cdx) development for the met inhibitor tepotinib in the mainland china market. the cdx test is based on burning rock's self-developed next generation sequencing (ngs)-based liquid biopsy solution, oncocompass target™ panel.
BNR Ratings Summary
BNR Quant Ranking